Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.

Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F.

Drug Saf. 2010 Apr 1;33(4):303-14. doi: 10.2165/11531850-000000000-00000.

PMID:
20297862
2.

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

Poluzzi E, Raschi E, Moretti U, De Ponti F.

Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):512-8. doi: 10.1002/pds.1746.

PMID:
19358226
3.

Torsades de pointes associated with fluoroquinolones.

Owens RC Jr, Ambrose PG.

Pharmacotherapy. 2002 May;22(5):663-8; discussion 668-72.

PMID:
12013370
4.

QT prolongation with antimicrobial agents: understanding the significance.

Owens RC Jr.

Drugs. 2004;64(10):1091-124. Review.

PMID:
15139788
5.

Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.

Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, Bennie M, Barbui C, Wettermark B, Sturkenboom M, De Ponti F.

PLoS One. 2013 Nov 20;8(11):e81208. doi: 10.1371/journal.pone.0081208. eCollection 2013.

6.

QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.

Pearson EC, Woosley RL.

Pharmacoepidemiol Drug Saf. 2005 Nov;14(11):747-53.

PMID:
15918160
7.

Antimicrobial-associated QT interval prolongation: pointes of interest.

Owens RC Jr, Nolin TD.

Clin Infect Dis. 2006 Dec 15;43(12):1603-11. Epub 2006 Nov 8. Review.

8.

Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.

Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F.

Drug Saf. 2013 Jun;36(6):467-79. doi: 10.1007/s40264-013-0032-z.

9.

How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.

Khadem TM, van Manen RP, Brown J.

Pharmacotherapy. 2014 Dec;34(12):1324-9. doi: 10.1002/phar.1519. Epub 2014 Nov 25.

PMID:
25421400
10.

Potential for linezolid-related blindness: a review of spontaneous adverse event reports.

Brown J, Aitken SL, van Manen RP.

Pharmacotherapy. 2011 Jun;31(6):585-90. doi: 10.1592/phco.31.6.585.

PMID:
21923442
11.

An experimental investigation of masking in the US FDA adverse event reporting system database.

Wang HW, Hochberg AM, Pearson RK, Hauben M.

Drug Saf. 2010 Dec 1;33(12):1117-33. doi: 10.2165/11584390-000000000-00000.

PMID:
21077702
12.

Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.

Aström-Lilja C, Odeberg JM, Ekman E, Hägg S.

Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):587-92. doi: 10.1002/pds.1607.

PMID:
18449951
13.

Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.

Roberto G, Piccinni C, D'Alessandro R, Poluzzi E.

Cephalalgia. 2014 Jan;34(1):5-13. doi: 10.1177/0333102413499649. Epub 2013 Aug 6.

PMID:
23921799
14.

Antimicrobial agents-associated with QT interval prolongation.

Bril F, Gonzalez CD, Di Girolamo G.

Curr Drug Saf. 2010 Jan;5(1):85-92. Review.

PMID:
20210724
15.

Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.

Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K.

Am J Health Syst Pharm. 2003 Dec 1;60(23):2479-83. Erratum in: Am J Health Syst Pharm. 2004 Jan;61(2):141.

PMID:
14686224
16.

The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?

Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ.

J Hosp Med. 2010 Apr;5(4):E8-16. doi: 10.1002/jhm.691. Review.

PMID:
20394022
17.

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N.

Drug Saf. 2002;25(4):263-86. Review.

PMID:
11994029
18.

Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.

Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y.

J Exp Clin Cancer Res. 2011 Oct 5;30:93. doi: 10.1186/1756-9966-30-93.

19.
20.
Items per page

Supplemental Content

Write to the Help Desk